JP2022527054A5 - - Google Patents

Info

Publication number
JP2022527054A5
JP2022527054A5 JP2021556771A JP2021556771A JP2022527054A5 JP 2022527054 A5 JP2022527054 A5 JP 2022527054A5 JP 2021556771 A JP2021556771 A JP 2021556771A JP 2021556771 A JP2021556771 A JP 2021556771A JP 2022527054 A5 JP2022527054 A5 JP 2022527054A5
Authority
JP
Japan
Prior art keywords
dry powder
pharmaceutical composition
approximately
composition according
microcrystalline particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023977 external-priority patent/WO2020198051A1/en
Publication of JP2022527054A publication Critical patent/JP2022527054A/ja
Publication of JP2022527054A5 publication Critical patent/JP2022527054A5/ja
Priority to JP2025002002A priority Critical patent/JP2025061049A/ja
Pending legal-status Critical Current

Links

JP2021556771A 2019-03-22 2020-03-20 吸入可能な乾燥粉末 Pending JP2022527054A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002002A JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822303P 2019-03-22 2019-03-22
US62/822,303 2019-03-22
PCT/US2020/023977 WO2020198051A1 (en) 2019-03-22 2020-03-20 Inhalable dry powders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002002A Division JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Publications (2)

Publication Number Publication Date
JP2022527054A JP2022527054A (ja) 2022-05-30
JP2022527054A5 true JP2022527054A5 (enExample) 2024-06-04

Family

ID=72608595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021556771A Pending JP2022527054A (ja) 2019-03-22 2020-03-20 吸入可能な乾燥粉末
JP2025002002A Pending JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002002A Pending JP2025061049A (ja) 2019-03-22 2025-01-06 吸入可能な乾燥粉末

Country Status (6)

Country Link
US (1) US20220241271A1 (enExample)
EP (1) EP3941438A4 (enExample)
JP (2) JP2022527054A (enExample)
CA (1) CA3133804A1 (enExample)
MX (2) MX428309B (enExample)
WO (1) WO2020198051A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4120854A4 (en) * 2020-03-19 2024-03-27 TFF Pharmaceuticals, Inc. INHALATION OF DRIED PARTICLES FOR ADMINISTRATION OF CANNABIS
WO2022081814A1 (en) * 2020-10-16 2022-04-21 Michael Ogburn Inhalable cannabinoid formulations
CA3235985A1 (en) * 2021-10-27 2023-05-04 Mannkind Corporation Methods and compositions for treating pulmonary hypertension

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017152D1 (de) * 1999-08-25 2005-02-03 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
HUE025151T2 (en) * 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
CN104383546B (zh) * 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) * 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
PT2621488T (pt) * 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
UA125747C2 (uk) * 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
IL260823B2 (en) * 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler

Similar Documents

Publication Publication Date Title
CN103052380B (zh) 包含治疗活性物质的湿润颗粒
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
JP4378057B2 (ja) 流動抵抗調節されたエアロゾル化活性薬剤送達
JP2023078269A5 (enExample)
JP2001517691A5 (enExample)
KR102579524B1 (ko) 폐, 비강, 설하 및/또는 인두 전달을 위해 조정된 하나 이상의 생활성 화합물로 로딩된 다공성 실리카 입자의 제조 방법
CN1303276A (zh) 包含紧密压实的固体药剂原料的药物释放系统
JPH08504438A (ja) 医薬活性化合物を投与するための系
BR112013029803B1 (pt) Composições de vancomicina em pó seco
JP2008518007A5 (enExample)
CN115955965A (zh) 用于治疗、改善或预防微生物感染的制造产品和方法
RU2007119721A (ru) Частицы для лечения легочной инфекции
JP2025061049A (ja) 吸入可能な乾燥粉末
ES3022184T3 (en) Rapamycin powders for pulmonary delivery
AU2025200588A1 (en) Surfactant Formulations for Inhalation
JP2021510723A5 (enExample)
KR20200115560A (ko) 흡입형 치료제의 고용량 전달
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
EP2627336A1 (en) Method for treating cystic fibrosis with inhaled denufosol
CA3085943A1 (en) Surfactant formulations for inhalation
Dhahir et al. Dry powder inhalers: main characteristics, classifications and novel drug delivery systems review
JP7679093B2 (ja) 呼吸器系傷害改善用医薬組成物
Kumar et al. Nanostructure-based pulmonary drug delivery systems for respiratory infections
Manzanedo et al. Formulation characterization of a novel levofloxacin pulmonary dry powder drug delivery technology
Vatanparast et al. Efficiency improvement of fluticasone propionate dry powder formulation for inhalation in pulmonary patients